Press release
Deadline in Lawsuit for Investors in shares of Correvio Pharma Corp. (NASDAQ: CORV) coming up
A Deadline is coming up on February 10, 2020 in the lawsuit for certain investors in Correvio Pharma Corp. (NASDAQ: CORV).
Investors who purchased shares of Correvio Pharma Corp. (NASDAQ: CORV) have certain options and there are strict and short deadlines running. Deadline: February 10, 2020. NASDAQ: CORV stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of Correvio Pharma Corp. (NASDAQ: CORV) common shares between October 23, 2018 and December 5, 2019, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between October 23, 2018 and December 5, 2019, the defendants made false and/or misleading statements and/or failed to disclose that the data supporting the Resubmitted NDA for Brinavess did not minimize the significant health and safety issues observed in connection with the drug's original NDA, that the foregoing substantially diminished the likelihood that the FDA would approve the Resubmitted NDA, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Correvio Pharma Corp. (NASDAQ: CORV) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline in Lawsuit for Investors in shares of Correvio Pharma Corp. (NASDAQ: CORV) coming up here
News-ID: 1917091 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Correvio
Scleroderma Therapeutics Market Is Expected To Exhibit Significant Growth Over 2 …
The global scleroderma therapeutics market is anticipated to showcase considerable growth during the forecast period. The rising FDA approvals, rising investment in the R&D of drugs for its treatment, the emergence of new novel therapies, and new product launches are some of the key factors contributing to the growth of the scleroderma therapeutics market across the globe. According to the American College of Rheumatology, scleroderma is a relatively rare autoimmune…
Scleroderma Therapeutics Market Growth, Analysis Report, Share, Trends and Overv …
The global scleroderma therapeutics market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, rising investment in the R&D of drugs for its treatment, the emergence of new novel therapies, and new product launches are some of the key factors contributing to the growth of the scleroderma therapeutics market across the globe. According to the American College of Rheumatology, scleroderma is a relatively rare…
Trifluoperazine Market 2021 Industry Analysis, Segmentation, Share, Size, Opport …
The Trifluoperazine Market research report added by MarketInsightsReports is an in-depth analysis of the latest trends, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research study provides market introduction, Trifluoperazine market definition, regional market scope, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect elements analysis, Trifluoperazine market size forecast, 100+ market data, Tables, Pie Chart,…
Global Scleroderma Therapeutics Market Size & Growth Analysis Report, 2020-2026
The global scleroderma therapeutics market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, rising investment in the R&D of drugs for its treatment, the emergence of new novel therapies, and new product launches are some of the key factors contributing to the growth of the scleroderma therapeutics market across the globe. According to the American College of Rheumatology, scleroderma is a relatively rare…
Scleroderma Therapeutics Market Growth, Trends, Industry Analysis and Forecast - …
The global scleroderma therapeutics market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, rising investment in the R&D of drugs for its treatment, the emergence of new novel therapies, and new product launches are some of the key factors contributing to the growth of the scleroderma therapeutics market across the globe. According to the American College of Rheumatology, scleroderma is a relatively rare…
Investigation for Long-Term Investors in shares of Correvio Pharma Corp. (NASDAQ …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Correvio Pharma Corp.
Investors who are current long term investors in Correvio Pharma Corp. (NASDAQ: CORV) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: CORV stocks follows a lawsuit filed against Correvio Pharma Corp. over…
